Bafna Pharmaceuticals Ltd
Company Profile
Business description
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
Contact
Thambu Chetty Street
New No. 68, Old No. 299, Bafna Towers
ChennaiTN600001
INDT: +91 4425267517
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
406
Stocks News & Analysis
stocks
Anglo American strikes deal to create a new copper giant
stocks
The ‘other’ AI chip behemoth that might just be getting started
stocks
Why ANZ changes aren’t just about cutting costs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,067.50 | 13.00 | -0.14% |
CAC 40 | 7,761.32 | 11.93 | 0.15% |
DAX 40 | 23,632.95 | 85.50 | -0.36% |
Dow JONES (US) | 45,490.92 | 220.42 | -0.48% |
FTSE 100 | 9,225.39 | 17.14 | -0.19% |
HKSE | 25,973.09 | 227.17 | -0.87% |
NASDAQ | 21,886.06 | 6.57 | 0.03% |
Nikkei 225 | 44,271.92 | 434.25 | 0.99% |
NZX 50 Index | 13,216.44 | 59.80 | -0.45% |
S&P 500 | 6,532.04 | 19.43 | 0.30% |
S&P/ASX 200 | 8,800.60 | 13.20 | -0.15% |
SSE Composite Index | 3,824.25 | 12.03 | 0.32% |